Correction: The original version of this story incorrectly stated that shares of Arena Pharmaceuticals closed the day lower.Shares of Arena Pharmaceuticals -- a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases -- closed up nearly 4% on Tuesday. Arena Pharmaceuticals has a market cap of $1.89 billion and is part of the health care sector. Shares are up 365.2% year to date as of the close of trading on Thursday. Currently there are two analysts that rate Arena Pharmaceuticals a buy, one analyst rates it a sell, and five rate it a hold. TheStreet Ratings rates Arena Pharmaceuticals as a sell. The area that we feel has been the company's primary weakness has been its meager revenue growth.
- You can view the full Arena Ratings Report.
- Find other investment ideas from our top rated ETFs lists.